

## Discussing the psychiatric manifestations of 22q11.2 deletion syndrome: an exploration of clinical practice among medical geneticists

Emily Morris, MSc<sup>1</sup>, Angela Inglis, MSc<sup>1,2</sup>, Jan Friedman, MD, PhD<sup>1</sup>, and Jehannine Austin, PhD<sup>1,2</sup>

<sup>1</sup>Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada

<sup>2</sup>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada

### Abstract

**Purpose**—The aim of this study was to determine the frequency with which medical geneticists discuss the psychiatric manifestations of 22q11.2 deletion syndrome (22q11DS) with families in relation to the frequency with which they discuss the other manifestations of the syndrome and to explore relationships between discussion of these features and stigma toward psychiatric disorders.

**Methods**—We surveyed medical geneticists in the United States and Canada regarding the frequency with which they discuss various features of 22q11DS with families in the context of four clinical scenarios in which only the age of the patient at diagnosis differed. Respondents also completed a 20-item validated psychometric measure of stigma towards psychiatric disorders.

**Results**—308/546 medical geneticists completed the survey (56% response rate). Psychiatric disorders were discussed significantly less often than other features of 22q11DS ( $p < 0.0001$ ), but psychiatric disorders were discussed significantly more often when the patient was 13 years old ( $p < 0.0001$ ), than when the patient was younger. Geneticists who discussed psychiatric disorders the least had significantly higher levels of stigma towards psychiatric disorders ( $p = 0.007$ ).

**Conclusion**—Psychiatric risks are less often discussed with families during childhood. Education for physicians to help reduce stigma towards psychiatric disorders (which may impede discussion of psychiatric disorders) may warrant exploration in this population.

### Keywords

22q11.2 deletion syndrome; medical geneticists; psychiatric disorders; stigma; mental illness

## INTRODUCTION

The 22q11.2 deletion syndrome (22q11DS) is the most common micro-deletion syndrome, affecting 1/4,000 newborns<sup>1</sup>. Individuals with 22q11DS present with a range of clinical manifestations, with congenital cardiac and palate defects, calcium deficiencies, immune

problems, and learning and cognitive disabilities amongst the most common<sup>2, 3</sup>. In addition, individuals with 22q11DS seem to have elevated rates of attention deficit hyperactivity disorder, anxiety, oppositional defiant disorder, autism spectrum disorders and approximately 25–30% of individuals develop schizophrenia or other psychotic disorders<sup>3–13</sup>.

In a 2008 study, parents of individuals with 22q11DS (N= 41) reported that psychiatric disorders were their second most important cause for concern related to the syndrome (after learning disabilities), and that of all the manifestations of the condition, psychiatric disorders were the source of their greatest anxiety<sup>14</sup>. In addition, and crucially, many parents reported that they did not receive information about the psychiatric risks associated with 22q11DS from their healthcare provider, but instead obtained information about these risks from the Internet<sup>14</sup>.

The group of physicians who are most often involved in delivering a diagnosis of 22q11DS are medical geneticists<sup>14</sup>. While a recent exploratory descriptive study examined the attitudes of 54 genetic counselors towards providing information about psychiatric risks<sup>15</sup> in the context of 22q11DS; there are no reported studies assessing the practices of medical geneticists in relation to discussing psychiatric manifestations of the condition.

Understanding how medical geneticists approach discussing the features of 22q11DS –and in particular the psychiatric features of this syndrome – is both important and timely given: a) the recent publication of international practice guidelines<sup>16</sup> which recommend that psychiatric symptoms be assessed repeatedly in children with 22q11DS from pre-school through adolescence; b) a recent report that mental health resources are underutilized by patients with 22q11DS<sup>17</sup> (which suggests that psychiatric disorders may be undiagnosed in this population), and c) the current movement towards including 22q11DS in some newborn screening programs<sup>18, 19</sup>.

It is relevant to note that psychiatric disorders are amongst the most profoundly stigmatized of all health conditions, and negative attitudes towards these conditions have been identified in many groups including the general public<sup>20–23</sup> students<sup>24</sup>, police<sup>25</sup>, mental health workers<sup>26, 27</sup>, and genetic counselors<sup>28, 29</sup>. Medical geneticists' attitudes towards individuals with psychiatric disorders, and relationships between these attitudes and clinical practice regarding disclosure of information about psychiatric risks have not been previously studied. It is possible, however, that medical geneticists who have more negative attitudes towards people with psychiatric disorders may be less likely to discuss psychiatric risks with families and individuals with 22q11DS.

We designed a cross-sectional survey-based study to test the hypotheses that: 1) overall, medical geneticists discuss psychiatric manifestations of 22q11DS less often than five other common features of the syndrome; 2) medical geneticists discuss the psychiatric disorders less frequently with families whose affected child is 12, and more frequently with families when the affected child is 13 years of age; and 3) medical geneticists who have more stigmatizing attitudes towards psychiatric disorders discuss psychiatric manifestations with

families less often than medical geneticists who have less stigmatizing attitudes towards psychiatric disorders.

## MATERIALS & METHODS

We obtained IRB approval for the study from the University of British Columbia (H11-00689). We obtained contact information for clinical geneticists through the membership directories of the Canadian College of Medical Geneticists and the American College of Medical Genetics. To each North American medical geneticist, we sent a survey package, including a consent form, the survey (described below), a stamped addressed return envelope, a pencil and a \$5.00 Starbucks giftcard<sup>30</sup>. Concurrently with the survey mail-out, emails were sent to inform potential participants about the study and to alert them to look out for the survey package in the mail. All respondents were given the option of completing the survey online (via [www.qualtrics.com](http://www.qualtrics.com)) or completing the hardcopy and returning it by mail. Reminder emails were sent approximately 4 and 6 weeks after the initial mail-out. Survey responses were collected between October 2011 and February 2012.

The survey included demographic items (gender, age, years in clinical practice, number of patients with 22q11DS seen per year, and personal experience with psychiatric disorders, see Table 1).

Respondents also reported the frequency (always, often, sometimes, rarely, never) with which they discuss six common features of 22q11DS (cardiac defects, immune problems, low serum calcium concentration, palate abnormalities, learning disabilities, and psychiatric disorders) with families in four different scenarios: S1 - when the affected individual is diagnosed prenatally or within the first year after birth, S2 - during childhood (1–12 years old), S3 - during adolescence (13–18 years old), and S4 - in adulthood (19 years old).

Medical geneticists who indicated that they “rarely” or “never” discuss psychiatric disorders for any of the scenarios were prompted to provide a rationale for their approach. We provided a list of six possible options (see Table 2). We also allowed respondents to indicate “other” and write in their own alternate answer.

The survey also included the *Opening Minds Scale for Health Care Providers* (OMS-HC) stigma scale, a 20-item validated measure, which assesses healthcare providers’ stigmatizing perceptions towards psychiatric disorders<sup>31</sup>. The OMS-HC stigma scale has five content areas: social distance, discrimination and devaluation, help seeking and disclosure, recovering, and social responsibility. Each item on the OMS-HC stigma scale is rated on a 5-point anchored Likert scale (1=strongly disagree, 5=strongly agree), and scale scores are derived by summing item scores and dividing by the number of items answered, with higher scores indicating greater stigmatization towards psychiatric disorders. Respondents were given the opportunity to provide additional comments about any of the survey questions.

### Data analyses

We excluded the number of survey packages that were returned to sender as a result of invalid delivery address from our total N for our response rate calculation. Medical

geneticists who indicated that they had never seen patients on a clinical basis, or had only seen patients in a non-relevant subspecialty (e.g. cancer) were also excluded. We considered a survey complete if the respondent had filled out one or more of the four scenarios about their clinical practice related to discussion of various manifestations of 22q11DS, or had completed 15 or more of the OMS-HC stigma scale items (we used mean item scores rather than total scores in analyzing data from the OMS-HC stigma scale), and did not exclude surveys returned with incomplete demographic information. Descriptive statistics were calculated for demographic data. To determine whether psychiatric disorders were discussed less frequently than other manifestations of 22q11DS (hypothesis 1), we generated composite “frequency of discussion” scores for each of the six manifestations of 22q11DS included in the questionnaire by scoring “always” as 5 and “never” as 1, and combining scores from all four scenarios. We then used repeated measures ANOVA to compare the frequency of discussion scores for the six manifestations of 22q11DS. In addition, we generated an overall “frequency of discussion” score for all of the non-psychiatric manifestations combined, and performed a T-test to compare frequency of discussion scores between psychiatric disorders and non-psychiatric manifestations.

To compare the frequency with which psychiatric disorders are discussed when the patient is an infant or child in relation to when the patient is an adolescent or adult, we used a T test to compare two mean “frequency of discussion” scores for psychiatric disorders. The first we produced by combining data from S1 and S2. The second we produced by combining data from S3 and S4.

To determine whether respondents with more stigmatizing attitudes towards psychiatric disorders discuss those disorders less with patients with 22q11DS, we used multivariate ANOVA to compare the OMS-HC stigma scale scores and scores for each of the five content areas of the OMS-HC stigma scale between those who reported that they “rarely or never” and those who “often or always” discuss psychiatric disorders.

In an exploratory analysis, we also used multivariate ANOVA to compare the frequency of discussion of psychiatric risks and OMS-HC stigma scale scores between groups of respondents based on number of cases of 22q11DS seen per year.

For all tests, a significance threshold ( $\alpha$ ) of  $p < 0.01$  was applied (to allow for the above five tests at a nominal overall significance level of 0.05).

We calculated internal consistency of the OMS-HC stigma scale for our population of medical geneticists using Cronbach’s alpha.

## RESULTS

Of 597 surveys sent out, 51 were excluded from analyses due to ineligibility (as described in the methods) or having an incorrect address and 308 completed surveys were returned ( $597 - 51 = 546$ ,  $308/546 = 56\%$ ). Most respondents completed the questionnaire by mail ( $n=231$ ), with the remainder ( $n=77$ ) completing it online. Demographic information and information about participants’ clinical experience with 22q11DS are displayed in Table I. All participants were medical geneticists who had provided clinical service at some point in

their career, and 92% (n=281) were currently practicing clinically, with a mean number of years in clinical practice of 19.8 years. 105 respondents provided comments in the optional open-ended question at the end of the survey.

### **Discussion of psychiatric versus other manifestations during counseling following diagnosis of 22q11DS**

Repeated measures ANOVA with a Greenhouse-Geisser correction showed that the overall mean frequency of discussion scores for the 6 manifestations of 22q11DS were statistically significantly different,  $F(3.417, 319.653) = 35.820, p < 0.0001$ . Psychiatric disorders were discussed significantly less often than cardiac defects ( $p < 0.0001$ ), palate defects ( $p = 0.004$ ), or learning disabilities ( $p < 0.0001$ ). There was no significant difference between frequency of discussion of psychiatric disorders and calcium deficiencies or immune problems. Table 5 in the supplementary data shows the breakdown of the number of respondents who indicated “rarely, never, sometimes, often, or always” discuss psychiatric disorders for each of the four scenarios.

Comparing the pooled frequency of discussion scores for all non-psychiatric manifestations to the frequency of discussion scores for psychiatric disorders revealed that the psychiatric manifestations of 22q11DS were discussed significantly less often than the other non-psychiatric features of the condition  $t(287) = -3.87, p < 0.0001$ . However, psychiatric disorders were discussed significantly more often when the patient was 13 years old compared to when the patient was 12 years old,  $t(258) = -5.578, p < 0.0001$  (See Figure 1). The rationales for not discussing psychiatric manifestations of 22q11DS when the diagnosis was made in S1 and S2 are shown in Table 2.

### **Stigmatizing attitudes towards mental illness and discussion of psychiatric risks**

Table 3 shows the data from the OMS-HC stigma scale overall (N=305) as well as its five content areas in this population of medical geneticists. Three respondents' OMS-HC stigma scale data were excluded due to being incomplete (i.e. <15 items answered). Internal consistency of the OMS-HC stigma scale in this population was good (Cronbach's alpha = 0.77). There were significant differences in OMS-HC stigma scale scores between medical geneticists who reported “rarely” or “never” discussing psychiatric disorders for at least one of the age groups (N=38) and those who “often” or “always” discussed psychiatric disorders,  $F(12, 590) = 1.857, p = 0.028$ ; Wilk's  $\lambda = 0.917$ . Table 4 shows further characteristics of these respondents. More specifically, respondents who “rarely” or “never” discussed psychiatric disorders had significantly different scores for both total OMS-HC,  $F(2, 301) = 4.418; p = 0.013$  and the social responsibility content area  $F(2, 301) = 6.399, p = 0.002$ .

Post Hoc Tukey's test showed that both OMS-HC stigma scale total score and the social responsibility content area score were significantly higher for respondents who “rarely” or “never” discuss psychiatric disorders ( $p = 0.007$  and  $p = 0.001$ , respectively). Scores in the discrimination and devaluation content area showed a trend ( $p = 0.016$ ) towards higher scores among respondents who “rarely” or “never” discuss psychiatric disorders.

## Exploratory Analyses

There were no significant differences in OMS-HC stigma scale scores between respondents who saw a larger or a smaller number of cases of 22q11DS per year. There was, however, a significant difference in the frequency of discussion of psychiatric disorders when the total sample was stratified by number of cases of 22q11DS seen per year,  $F(5,282)=5.487$ ,  $p<0.0001$ . Tukey Post Hoc comparisons showed respondents who reported that those who saw 10 patients with 22q11DS per year discussed psychiatric disorders significantly more often than respondents who reported that they saw 0–1 cases per year ( $p<0.0001$ ).

## DISCUSSION

This study was the first to explore medical geneticists' approaches to discussing features of 22q11DS with families at the time of counseling following diagnosis, and the first to explore stigmatizing attitudes towards psychiatric disorders among medical geneticists. We found that the psychiatric manifestations of 22q11DS were discussed with families less often than the other features of 22q11DS overall (when all categories of age of patient were pooled). However, subsequent analyses supported our hypothesis by showing that the frequency with which psychiatric disorders were discussed was highly dependent on the age of the patient at diagnosis of 22q11DS – psychiatric disorders were significantly less likely to be discussed when the diagnosis of 22q11DS was being made in childhood, and significantly more likely to be discussed when the affected individual was an adolescent or adult. Our formulation of this hypothesis arose as a result of our perception that the bulk of the literature concerning psychiatric disorders and 22q11DS focused on psychotic disorders (and in particular schizophrenia), which tend to emerge during adolescence/young adulthood. Indeed, the rationales most frequently provided by respondents in this study for not discussing psychiatric disorders were: “Psychiatric disorders are not a relevant issue for patients with 22q11DS at this age”, and “I would discuss risks for psychiatric disorders at a follow-up appointment when the child is older”. These data are congruent with findings of a recent descriptive study by Martin *et al.*, which showed that genetic counselors were less likely to discuss psychiatric disorders than other features of 22q11DS during diagnoses in infancy, because these issues would be addressed in follow up visits<sup>15</sup>.

This rationale indicates that perhaps there are some gaps in awareness amongst medical geneticists regarding risks for childhood onset psychiatric conditions associated with 22q11DS<sup>7, 12, 13</sup> and suggests that perhaps respondents were focusing primarily on psychotic illnesses when responding to this question. Indeed, some comments spontaneously volunteered by participants indicate a potential focus on psychotic disorders. For example:

“Parents want to know that their child is going to be ok NOW before they want details about things that MIGHT happen in 21 years.”

Regardless, however, parents of individuals with 22q11DS have indicated that they would prefer to receive information about potential psychiatric symptoms prior to the age of onset<sup>15</sup> (i.e. when the child is younger). In addition, this approach necessitates another clinic visit when the child is older in order for a family to find out about psychiatric manifestations of the illness from their medical geneticist. However, parents have reported that they were

not told about the psychiatric manifestations of 22q11DS by their healthcare providers<sup>14</sup>. Furthermore, studies show significant underutilization of mental health resources (both pharmaceutical and non-pharmaceutical) by individuals with 22q11DS<sup>17</sup> (perhaps reflecting under-recognition of psychiatric manifestations of the condition). Taken together, these findings suggest a number of possibilities: first, perhaps these follow up visits are happening, and parents are, in fact, being told about the psychiatric disorders associated with the condition, but fail to remember (perhaps as a result of information overload); second, perhaps follow up visits are happening, but psychiatric disorders are not discussed; third, perhaps these follow-up visits with medical geneticists - at which psychiatric disorders would be discussed - may not routinely be occurring. Indeed, one respondent volunteered:

“... these children don’t come back to genetics typically”

If these patients are in fact often not seen for follow-up visits at medical genetics (perhaps even despite best intentions on the part of the clinician), this could be a crucial factor in determining whether families learn about psychiatric manifestations of 22q11DS from a healthcare professional, and suggests that although current guidelines recommend that genetic counseling for patients with 22q11DS be repeated at each life stage, especially during the transitional years from childhood to adulthood<sup>16, 17</sup>, this may not be happening in practice. This represents an important area for future research, especially given the current discussion regarding considering whether 22q11DS is a condition that should potentially be included in newborn screening panels<sup>18, 32</sup>. If 22q11DS is included in newborn screening, diagnoses will increasingly be made at earlier ages. Since follow up visits may not be occurring as often as intended, it will be important to identify strategies to facilitate return visits for patients and their families.

Furthermore, recent international practice guidelines for the management of patients with 22q11DS recommend repeated psychiatric assessments beginning in early childhood<sup>16</sup> as early intervention and effective treatments greatly improve prognosis and reduce morbidity<sup>33–35</sup>. However, if psychiatric manifestations of the syndrome are not discussed during childhood, appropriate psychiatric care and assessments are unlikely to occur. Thus, an argument could be made that despite the fact that there is a lot of information to convey to parents when a diagnosis of 22q11DS is made in a child, it may be appropriate to include psychiatric manifestations of the condition in the discussion. It is certainly true that medical geneticists are not the only physician group involved in providing care for these patients. Indeed, pediatricians and/or family physicians are better placed to provide long-term ongoing care, but may lack familiarity with the various manifestations of rare genetic conditions – this remains the specialist domain of the medical geneticist<sup>17</sup>.

### **Discussion of psychiatric risks: an issue of stigma?**

Our results show that the frequency with which medical geneticists discuss psychiatric manifestations of 22q11DS is related to stigma: those who did not discuss this issue had significantly more stigmatizing attitudes towards mental illness overall. On closer inspection, this significant result was driven by differences in the social responsibility content area. The three items in this content area are thematically the most closely linked to attitudes towards providing information and support to patients about psychiatric disorders.

For example, one item in the social responsibility content area is: “Healthcare providers do not need to be advocates for people with mental illness”, intuitively it seems consistent that those who agree with this statement may be less likely to provide information about psychiatric disorders in the context of 22q11DS. Our findings, which link healthcare professionals’ own stigmatizing attitudes towards psychiatric disorders with their approach to disclosing risks for psychiatric disorders are congruent with, yet expand upon, the findings of recent work. A recent study showed that genetic counselors were hesitant to disclose the risk for psychiatric disorders to families due – in part - to concerns about societal perceptions of mental illness and the impact on how parents treat the affected child. The influence of healthcare professionals’ own stigma towards psychiatric disorders on clinical practice, however, was not explicitly explored<sup>15</sup>.

Many respondents provided comments in the designated space at the end of the survey, some of which provide further insight into respondents’ attitudes towards mental illness. Some of these quotes may be interpreted as illustrating a more negative attitude towards certain kinds of psychiatric disorders (such as schizophrenia) than others (e.g. anxiety/depression) – a phenomenon that has been observed in studies in other populations<sup>36, 37</sup>. For example:

“Other illnesses (e.g. anxiety and depression) are more easily seen as compassion-worthy. Still others (schizophrenia and bipolar disorder) may best be served by being classed as neurological/neurodegenerative disorders.”

“A person who takes Prozac to improve mood is not the same as a schizophrenic with a record of frequent drug holidays.”

The OMS-HC stigma scale, however, does not distinguish between different psychiatric diagnoses. This suggests that although we clearly showed that those who rarely or never discuss psychiatric disorders in clinical practice had higher levels of stigmatizing attitudes towards psychiatric disorders (broadly defined) both overall, and in the social responsibility content area, had the instrument been targeted specifically at a psychiatric disorder such as schizophrenia, we may also have found significant differences in additional content areas. This may constitute a fruitful area for future investigation.

Although psychiatric disorders were discussed significantly less often than other manifestations of 22q11DS overall, and when diagnosis was established prenatally or during childhood in particular, it is interesting to note that only 38 respondents indicated that they rarely or never discuss psychiatric risks with families. These results suggest that even when diagnoses of 22q11DS are made during childhood, most medical geneticists discuss psychiatric disorders at least some of the time. It is important to consider how these data can be reconciled with the findings of previous work, which showed that parents reported not receiving information about the psychiatric manifestations of 22q11DS from their healthcare providers<sup>14</sup>. First, in addition to the medical geneticists who indicated “rarely” or “never” discussing psychiatric disorders, many others (see Table 5 in supplementary data) indicated “sometimes” or “often”, rather than “always”. Therefore, altogether, there is likely to be a substantial number of patients who receive a diagnosis of 22q11DS where psychiatric risks are not discussed, and, as a result, many parents are indeed uninformed of these risks. Second, perhaps for the most part medical geneticists do in fact usually tell parents about



psychiatric manifestations of 22q11DS, but, due to the overwhelming amount of information they receive, parents do not recall having received this piece of information as it lacks immediate salience.

Third, perhaps the 2008 study, which identified the gap in information about psychiatric disorders, was affected by selection bias – those parents who did not receive this kind of information were more likely to participate<sup>14</sup>. Alternatively, perhaps medical geneticists who participated in the current study were those who are more cognizant of and likely to discuss psychiatric disorders related to 22q11DS. However, it is worthy of note that our response rate was very respectable (>50%), and that even among medical geneticists who participated in this study it seems that there may in fact be a need for education about the psychiatric manifestations of 22q11DS, as illustrated by a quote from one participant:

“Cardiac defects and calcium defects can be fixed, immune deficiency can be managed, few disabilities can get early intervention. How helpless do you want to make parents feel about something we don’t know the frequency of and that we don’t know how to prevent?”

In fact, there is good information about the frequency with which individuals with 22q11DS develop psychiatric disorders<sup>3</sup>. Also, as discussed above, while there is no prevention *per se*, early intervention for psychiatric disorders improves prognosis. Together, this suggests a possible role for continuing education for medical geneticists regarding psychiatric disorders in relation to 22q11DS; one participant expressed a sentiment to this effect in their comments on the survey:

“I became more aware of the psychiatric aspect (potential) of 22q deletion syndrome after diagnosing this syndrome in a teenaged patient who presented with psychosis. I think there needs to be more education....”

As medical geneticists who reported seeing the most patients with 22q11DS (10 or more cases per year) discussed psychiatric disorders more often than those who saw the fewest (0–1 cases per year), it seems that awareness and adequate education about the disorder and the associated psychiatric problems may indeed play an important role in discussion practices.

A fourth potential explanation for the apparent potential discrepancy between Hercher *et al*’s study and our current study is that, as with all studies using self-report surveys, social desirability is a potential limitation – thus, it is possible that respondents do not actually discuss psychiatric manifestations of 22q11DS as frequently as they indicated.

## Limitations

Potential limitations relating to ascertainment bias and social desirability that are common to self-report cross-sectional survey type studies have been discussed above. Other potential limitations relate to the fact that some of the respondents did not see patients from all four diagnostic scenarios (e.g. only seeing paediatric patients), limiting our ability to compare all responses across all time points. As the OMS-HC stigma scale and the survey ask about psychiatric disorders in general, attitudes, opinion, and clinical practices relating to discrete diagnoses cannot be determined separately – this would be a potentially fruitful avenue of investigation for future work.

## Conclusion

Our data show that medical geneticists discuss psychiatric manifestations of 22q11DS less frequently with families when the diagnosis is made in a child, and that frequency of discussion is associated with physicians' attitudes towards psychiatric disorders and the misperception that these conditions occur exclusively during adolescence/adulthood. Thus, future studies might attempt to identify how, when and by whom the psychiatric manifestations of the condition could be routinely brought to parents' attention, such that those individuals who develop symptoms might be identified and treated in a timely fashion. Our data also suggest that implementing changes in training and continuing education for medical geneticists to reduce stigmatizing attitudes towards psychiatric disorders <sup>23, 29, 38–40</sup>, and to increase awareness of the types and typical ages of onset of psychiatric conditions that people with 22q11DS can experience, has the potential to positively influence clinical practice.

## Acknowledgments


This study was funded by the Rare Disease Foundation, the Mitacs Accelerate Research Internship program, BC Mental Health and Addiction Services (BCMHAS), and the UBC Genetic Counseling program. The authors thank Maggie Hamidi, Anna Cantor, John Morris and Patricia Birch for help with various aspects of the study, and Boris Kuzeljevic for help with the statistical analyses. JA was supported by the Canada Research Chairs Program, the Michael Smith Foundation for Health Research, and BCMHAS.

## References

1. Devriendt K, Fryns JP, Mortier G, van Thienen MN, Keymolen K. The annual incidence of DiGeorge/velocardiofacial syndrome. *J Med Genet.* 1998; 35:789–790.
2. Shprintzen RJ. Velo-cardio-facial syndrome: 30 Years of study. *Dev Disabil Res Rev.* 2008; 14:3–10. [PubMed: 18636631]
3. Bassett AS, Chow EW, Husted J, et al. Clinical features of 78 adults with 22q11 Deletion Syndrome. *Am J Med Genet A.* 2005; 138:307–313. [PubMed: 16208694]
4. Green T, Gothelf D, Glaser B, et al. Psychiatric disorders and intellectual functioning throughout development in velocardiofacial (22q11.2 deletion) syndrome. *J Am Acad Child Adolesc Psychiatry.* 2009; 48:1060–1068. [PubMed: 19797984]
5. Philip N, Bassett A. Cognitive, behavioural and psychiatric phenotype in 22q11.2 deletion syndrome. *Behav Genet.* 2011; 41:403–412. [PubMed: 21573985]
6. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio- facial syndrome. *Arch Gen Psychiatry.* 1999; 56:940–945. [PubMed: 10530637]
7. Niklasson L, Rasmussen P, Oskarsdottir S, Gillberg C. Attention deficits in children with 22q.11 deletion syndrome. *Dev Med Child Neurol.* 2005; 47:803–807. [PubMed: 16288669]
8. Williams NM, Owen MJ. Genetic abnormalities of chromosome 22 and the development of psychosis. *Curr Psychiatry Rep.* 2004; 6:176–182. [PubMed: 15142470]
9. Bassett AS, Hodgkinson K, Chow EW, Correia S, Scutt LE, Weksberg R. 22q11 Deletion Syndrome in Adults with Schizophrenia. *Am J Med Genet.* 1998; 81:328–337. [PubMed: 9674980]
10. Debbane M, Glaser B, David MK, Feinstein C, Eliez S. Psychotic symptoms in children and adolescents with 22q11.2 deletion syndrome: Neuropsychological and behavioral implications. *Schizophr Res.* 2006; 84:187–193. [PubMed: 16545541]
11. Jolin EM, Weller RA, Weller EB. Psychosis in children with velocardiofacial syndrome (22q11.2 deletion syndrome). *Curr Psychiatry Rep.* 2009; 11:99–105. [PubMed: 19302762]
12. Niklasson L, Rasmussen P, Oskarsdottir S, Gillberg C. Autism, ADHD, mental retardation and behavior problems in 100 individuals with 22q11 deletion syndrome. *Res Dev Disabil.* 2009; 30:763–773. [PubMed: 19070990]

13. Vorstman JA, Breetvelt EJ, Thode KI, Chow EW, Bassett AS. Expression of autism spectrum and schizophrenia in patients with a 22q11.2 deletion. *Schizophr Res.* 2012
14. Hercher L, Bruenner G. Living with a child at risk for psychotic illness: the experience of parents coping with 22q11 deletion syndrome: an exploratory study. *Am J Med Genet A.* 2008; 146A: 2355–2360. [PubMed: 18698620]
15. Martin N, Mikhaelian M, Cytrynbaum C, et al. 22q11.2 Deletion Syndrome: Attitudes towards Disclosing the Risk of Psychiatric Illness. *J Genet Couns.* 2012
16. Bassett AS, McDonald-McGinn DM, Devriendt K, et al. Practical guidelines for managing patients with 22q11.2 deletion syndrome. *J Pediatr.* 2011; 159:332–9.e1. [PubMed: 21570089]
17. Young AS, Shashi V, Schoch K, Kwapil T, Hooper SR. Discordance in Diagnoses and Treatment of Psychiatric Disorders in Children and Adolescents with 22q11.2 Deletion Syndrome. *Asian J Psychiatr.* 2011; 4:119–124. [PubMed: 21743818]
18. Bales AM, Zaleski CA, McPherson EW. Patient and family experiences and opinions on adding 22q11 deletion syndrome to the newborn screen. *J Genet Couns.* 2010; 19:526–534. [PubMed: 20496046]
19. Hallberg U, Oskarsdottir S, Klingberg G. 22q11 deletion syndrome - the meaning of a diagnosis. A qualitative study on parental perspectives. *Child Care Health Dev.* 2010; 36:719–725. [PubMed: 20533913]
20. Corrigan PW, Watson AC. The stigma of psychiatric disorders and the gender, ethnicity, and education of the perceiver. *Community Ment Health J.* 2007; 43:439–458. [PubMed: 17876705]
21. Kobau R, Diiorio C, Chapman D, Delvecchio P. SAMHSA/CDC Mental Illness Stigma Panel Members. Attitudes about mental illness and its treatment: validation of a generic scale for public health surveillance of mental illness associated stigma. *Community Ment Health J.* 2010; 46:164–176. [PubMed: 19330448]
22. Brown SA. Factors and measurement of mental illness stigma: a psychometric examination of the Attribution Questionnaire. *Psychiatr Rehabil J.* 2008; 32:89–94. [PubMed: 18840562]
23. Chan JY, Mak WW, Law LS. Combining education and video-based contact to reduce stigma of mental illness: “The Same or Not the Same” anti-stigma program for secondary schools in Hong Kong. *Soc Sci Med.* 2009; 68:1521–1526. [PubMed: 19282079]
24. Keane M. Contemporary beliefs about mental illness among medical students: Implications for education and practice. *Academic Psychiatry.* 1990; 3:172–177.
25. Watson AC, Corrigan PW, Ottati V. Police officers’ attitudes toward and decisions about persons with mental illness. *Psychiatr Serv.* 2004; 55:49–53. [PubMed: 14699200]
26. Nordt C, Rossler W, Lauber C. Attitudes of mental health professionals toward people with schizophrenia and major depression. *Schizophr Bull.* 2006; 32:709–714. [PubMed: 16510695]
27. Schulze B. Stigma and mental health professionals: a review of the evidence on an intricate relationship. *Int Rev Psychiatry.* 2007; 19:137–155. [PubMed: 17464792]
28. Monaco LC, Conway L, Valverde K, Austin JC. Exploring Genetic Counselors’ Perceptions of and Attitudes towards Schizophrenia. *Public Health Genomics.* 2009
29. Anderson K, Austin JC. Effects of a Documentary Film on Public Stigma Related to Mental Illness Among Genetic Counselors. *J Genet Couns.* 2011
30. Church AH. Estimating the effect of incentives on mail survey response rates: A meta analysis. *Public Opinion Quarterly.* 1993; 57:62–79.
31. Kassam A, Papish A, Modgill G, Patten S. The development and psychometric properties of a new scale to measure mental illness related stigma by health care providers: The Opening Minds Scale for Health Care Providers (OMS-HC). *BMC Psychiatry.* 2012; 12:62. [PubMed: 22694771]
32. Sorensen KM, Agergaard P, Olesen C, et al. Detecting 22q11.2 deletions by use of multiplex ligation-dependent probe amplification on DNA from neonatal dried blood spot samples. *J Mol Diagn.* 2010; 12:147–151. [PubMed: 20075206]
33. Bertolote J, McGorry P. Early intervention and recovery for young people with early psychosis: consensus statement. *Br J Psychiatry Suppl.* 2005; 48:s116–9. [PubMed: 16055800]
34. Onwumere J, Bebbington P, Kuipers E. Family interventions in early psychosis: specificity and effectiveness. *Epidemiol Psychiatr Sci.* 2011; 20:113–119. [PubMed: 21714356]

35. Valmaggia LR, McGuire PK, Fusar-Poli P, Howes O, McCrone P. Economic impact of early detection and early intervention of psychosis. *Curr Pharm Des.* 2012; 18:592–595. [PubMed: 22239592]
36. Kohlbauer D, Meise U, Schenner M, et al. Does education focusing on depression change the attitudes towards schizophrenia? A target-group oriented anti-stigma-intervention. *Neuropsychiatr.* 2010; 24:132–140. [PubMed: 20605009]
37. Reavley NJ, Jorm AF. Stigmatizing attitudes towards people with mental disorders: findings from an Australian National Survey of Mental Health Literacy and Stigma. *Aust N Z J Psychiatry.* 2011; 45:1086–1093. [PubMed: 22023236]
38. Mann CE, Himelein MJ. Putting the person back into psychopathology: an intervention to reduce mental illness stigma in the classroom. *Soc Psychiatry Psychiatr Epidemiol.* 2008; 43:545–551. [PubMed: 18286216]
39. Weiss MG, Ramakrishna J. Stigma interventions and research for international health. *The Lancet.* 2006; 367:536–538.
40. Corrigan PW, Larson J, Sells M, Niessen N, Watson AC. Will filmed presentations of education and contact diminish mental illness stigma? *Community Ment Health J.* 2007; 43:171–181. [PubMed: 16988883]



**Figure 1.**

Breakdown of the mean frequency of discussion scores for each of the six main features of 22q11DS (cardiac defects, palate defects, calcium deficiencies, immune problems, learning disabilities, and psychiatric disorders) at S1 (prenatal to <1 year), S2 (1–12 years), S3 (13–18 years), and S4 (19 years). Standard Error Mean error bars are shown.

**Table 1**

Demographic information of medical geneticists (N=308). Respondents could select more than one option for “Personal experience with mental illness.” Total numbers may not add up to 308 due to missing data points, as some respondents chose not to answer certain demographic characteristics.

Characteristic	n	%
Gender <sup>1</sup>		
Male	141	46.69
Female	161	53.31
Age <sup>2</sup>		
< 30 years	0	0.00
31 – 40 years	36	11.84
41 – 50 years	74	24.34
51 – 60 years	122	40.13
61+	72	23.68
Location of clinical practice <sup>3</sup>		
Other	1	0.33
Canada	48	15.89
United States	253	83.77
Have you ever had a patient with 22q11DS? <sup>4</sup>		
Yes	295	96.40%
No	11	3.6%
Number of cases of 22q11DS per year <sup>5</sup>		
0 – 1 cases	64	22.07
2 – 3 cases	93	32.07
4 – 6 cases	69	23.79
7 – 9 cases	21	7.24
10 + cases	43	14.83
Personal experiences with mental illness		
I have a mental illness	14	3.23
I have one or more family member(s) with mental illness	141	32.49
I have a close friend who has a mental illness	68	15.67
I have a work colleague with a mental illness	69	15.90
I have worked/volunteered with a mental health organization	28	6.45
Other (respondents could elaborate on experience)	44	10.14
I do not have any acquaintances with a mental illness	70	16.13

<sup>1</sup>Six individuals did not provide their sex.

<sup>2</sup>Four individuals did not provide their age.

<sup>3</sup>Six individuals did not provide their location of clinical practice.

<sup>4</sup>Two individuals did not provide if they have ever had a patient with 22q11DS.

<sup>5</sup>Five individuals who indicated that they have seen patients with 22q11DS did not indicate how many cases of 22q11DS they see per year.

**Table 2**

Rationale provided by respondents who indicated rarely or never discussing psychiatric disorders during diagnosis of 22q11.2DS in which diagnosis was made at S1 (prenatal- < 1 year) or S2 (1–12 years) (N=38). Respondents who indicated “other” were able to provide their own rationale. Respondents were able to check more than one response, if they desired.

<b>Rationale</b>	<b>n</b>	<b>%</b>
The chance of psychiatric disorders in patients with 22q11DS is very low	4	7
I do not want to worry parents about psychiatric disorders.	5	8
Psychiatric disorders are not a significant issue; other conditions are more important	3	5
Discussing the risks for psychiatric disorders is the responsibility of another professional (e.g. psychiatrist)	1	2
Psychiatric disorders are not a relevant issue for patients with 22q11DS at this age	17	28
I would discuss risks for psychiatric disorders at a follow- up appointment when the child is older.	23	38
Other	8	13

**Table 3**

Descriptive statistics from the OMS-HC stigma scale (N=305). 283 respondents completed all 20 items; the remaining 22 respondents answered 15 or more of the total 20 items.

	<b>Minimum</b>	<b>Maximum</b>	<b>Mean</b>	<b>Standard Deviation</b>
Total mean item score	1.2	3.3	2.3	0.368
Social distance mean item score	1.0	3.8	2.2	0.514
Discrimination and devaluation mean item score	1.1	4.0	2.3	0.489
Help seeking mean item score	1.0	4.5	3.0	0.606
Recovering mean item score	1.0	5.0	2.9	0.979
Social responsibility mean item score	1.0	3.3	1.9	0.766



**Table 4**

Demographic characteristics of those respondents who indicated they “rarely” or “never” discuss psychiatric disorders during diagnosis of 22q11DS for at least one of the clinical scenarios (S1, S2, S3, or S4) (N=38).

Characteristic	N	%
Male	19	50.0
Female	19	50.0
Age <sup>1</sup>		
31–40	4	11.1
41–50	13	36.1
51–60	9	25.0
61+	10	27.8
Currently in clinical practice		
Yes	36	94.7
No	2	5.3
Canada	4	10.5
United States	34	89.5
Number of cases of 22q11DS seen per year <sup>2</sup>		
0–1	12	32.4
2–3	11	29.7
4–6	11	29.7
7–9	1	2.7
10+	2	5.4

<sup>1</sup>Two individuals did not provide their age.

<sup>2</sup>One individual did not provide the number of cases per year.